The global bioinformatics market size was valued at USD 10.1 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 13.7% from 2023 to 2030. Growing demand in the process of novel drug R&D and private and public funding initiatives to support R&D activities are expected to be the key factors driving the market during the forecast period. Furthermore, the introduction of user-friendly and readily available bioinformatics software such as RasMol, AUTODOCK, BALL, and Bioclipse, and growing market usage of these tools for the accurate and effective analysis of biomarkers discovery programs that assist in toxicity detection during the initial stage of the drug development process are expected to drive industry growth over the forecast period.
Bioinformatics software and tools are being used as integrated solutions that provide algorithms and statistical methodologies for data analysis and help integrate data management and analysis for applications such as next-generation sequencing, genomic and proteomic structuring, modeling, and three-dimensional drug designing. Increasing R&D initiatives in the proteomics and genomics market, including other related ‘-omics’ fields, are further expected to support market growth to meet data storage and analysis demands.
According to an article published by Stanford Medicine in January 2022, research conducted by Stanford scientists showed that a DNA sequencing technique could sequence a human genome in about 8 hours. Such developments can boost demand for genomics and, consequently, the bioinformatics sector. Bioinformatics data storage and analysis applications are capable of storing a large amount of genomic and proteomic information to facilitate research activities in fields ranging from aging and carcinogenesis to preventive therapy for genetic diseases. This factor is also expected to significantly contribute to the growth of this industry over the forecast period.
The COVID-19 pandemic has significantly impacted the bioinformatics market. Researchers and physicians resorted to bioinformatics to help them comprehend the virus and create diagnostic tests and cures. As a result, the demand for bioinformatics tools and services showed a noticeable surge during this period.
The genomics application segment accounted for a significant revenue share in 2022. Growing demand for pharmacogenomics in drug development and sequence screening and the introduction of technological advancements aimed at managing large sets of genomic data are key factors accounting for this large share. Based on application, the market is segmented into genomics, molecular phylogenetics, metabolomics, proteomics, transcriptomics, cheminformatics and drug designing, and others.
The cheminformatics segment is expected to expand substantially during the forecast period, wherein increasing demand for biomarker discovery and development is the primary reason for this expected growth. Cost reductions in the drug development process, reduced time for introducing a new drug in the market, and an increase in the success rate of drug discovery by cheminformatics and drug designing are expected to further boost this segment's growth.
Researchers may quickly analyze and interpret vast amounts of chemical and biological data by integrating bioinformatics with cheminformatics and drug designing, which results in more focused and successful drug development efforts. For instance, in June 2021, the U.S. Food and Drug Administration and the Center for Drug Evaluation and Research (CDER) sanctioned 26 new molecular entities (NMEs), which will drive the growth of research and development activities.
The area of proteomics has also experienced extensive R&D investments in recent years, and bioinformatics is integral in analyzing and managing the resultant data. Also, this makes it simpler to handle heterogeneous and large data sets, introduce new algorithms, and improve the knowledge discovery procedure.
The bio-content management segment led the market with a revenue share of 39.6% in 2022. High usage rates of bioinformatics tools and software in database management are one of the primary reasons attributed to its large share, as it efficiently provides easy data sharing with external databases and resources and promotes data integration. The genetic sequence analysis platforms segment is also expected to witness significant growth during the forecast period due to the rapidly growing demand for whole-genome and exome sequencing technologies as a result of exponentially reduced costs of genetic sequencing.
Data compatibility and improved data sharing and collaboration are ensured by adherence to guidelines set out by organizations such as the Human Genome Variation Society (HGVS), Genomic Data Commons (GDC), and Minimum Information About a Microarray Experiment (MIAME). In April 2022, ATCC entered into an agreement with Qiagen to share sequencing data from its collection of animal and human cell lines and biological materials. Qiagen will form a database from this information and use it in the development and delivery of high-value content for the pharma and biotechnology industries, which helps in knowing about new diseases and the development of new therapeutic targets.
On the basis of product, the market is segmented into bioinformatics platforms, bioinformatics services, and bio-content management. The bioinformatics services segment is expected to expand at the fastest rate of 14.6% CAGR during the forecast period. The major application area in the bioinformatics sector has been genomics, which involves the analysis of an organism's entire DNA sequence.
The demand for bioinformatics tools and services has increased due to the growing availability of genetic data from many sources, including next-generation sequencing technologies, in genomics research and clinical applications. For instance, The National Institute of Technology, Rourkela, India, launched the Centre for Bioinformatics and Computational Biology (CBCB) in July 2021 to assist in the development of biomarkers and therapeutic strategies for various diseases using big data analytics. Launching these centers in growing markets helps companies in boosting market growth.
The bioinformatics platforms segment is expected to grow significantly during the forecast period. Collaboration and data sharing between academics are frequently made easier by bioinformatics platforms. The increasing volume and complexity of biological data, growing demand for personalized medicine, and increasing availability of cloud computing are driving segment growth. The development of new sequencing technologies is also driving the growth of bioinformatics platforms.
Furthermore, the introduction of new and advanced technologies is expected to boost market growth over the forecast period. For instance, in June 2022, My Intelligent Machines (MIMs) launched its software for drug development in oncology. In another instance, in March 2022, ARUP launched Rio, which is a bioinformatics analytics platform that helps generate faster results for next-generation sequencing tests.
North America dominated the market and accounted for a revenue share of 43.6% in 2022. The majority of the revenue is generated from the U.S. and Canada, driven by the extensive presence of top research organizations, academic institutions, and bioinformatics businesses in the region. Increasing investments in the research & development of new and innovative technologies related to molecular biology and genome sequencing is expected to boost the regional market. For instance, in June 2022, LatchBio, California’s biotechnology research startup, launched an end-to-end bioinformatics platform that handles big biotech data to accelerate scientific discovery.
Asia Pacific is poised to be the fastest-growing regional market with a CAGR of 18.4% during the projection period. The presence of skilled and trained bioinformaticians and the expected strong development of the region’s IT sector are anticipated to enhance the capability of providing outsourcing services to developed economies. Supportive government policies are also expected to drive the growth of this region over the forecast period.
For instance, China has initiated programs such as the China Precision Medicine Initiative and the China National GeneBank that emphasize the application of bioinformatics to the areas of genomics research and healthcare. Similarly, nations such as India and South Korea have put in place programs to strengthen bioinformatics capabilities and encourage innovation in this space. Government funding and support encourage the adoption and expansion of bioinformatics solutions.
Industry participants are involved in the R&D of genetic and proteomic sequencing to enhance DNA and RNA sequencing capabilities to reduce genome sequencing costs. The development of next-generation sequencing technologies is expected to drive the bioinformatics industry over the forecast period. For instance, in March 2021, Agilent Technologies Inc. introduced a highly customizable and robust system ‘SureSelect’ for the analysis of human exome.
In another instance, in January 2020, Charles River Laboratories Inc. collaborated with Fios Genomics to gain access to the latter’s expertise in biology and bioinformatics. Furthermore, in January 2021, Illumina announced the launch of a cloud-based bioinformatics platform, as well as the Pan-Cancer IVD Test to improve its cancer detection efforts. Following are some of the major players in the global bioinformatics market:
Seven Bridges Genomics
Thermo Fisher Scientific
Market size value in 2023
USD 11.6 billion
Revenue forecast in 2030
USD 28.5 billion
CAGR of 13.7% from 2023 to 2030
Base year for estimation
2018 - 2021
2023 - 2030
Revenue in USD million/billion and CAGR from 2023 to 2030
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Product, application, region
North America; Europe; Asia Pacific; Latin America; MEA
U.S.; Canada; UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
DNAnexus Inc.; Seven Bridges Genomics; BGI Group; Partek Inc.; Thermo Fisher Scientific; Qiagen; Agilent Technologies; Illumina; PerkinElmer
Free report customization (equivalent up to analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global bioinformatics market report based on product, application, and region:
Product Outlook (Revenue, USD Million, 2018 - 2030)
Sequence Analysis Platforms
Sequence Manipulation Platforms
Sequence Alignment Platforms
Structural and Functional Analysis Platforms
Application Outlook (Revenue, USD Million, 2018 - 2030)
Cheminformatics and drug designing
Regional Outlook (Revenue, USD Million, 2018 - 2030)
Middle East and Africa
b. The global bioinformatics market size was estimated at USD 10.1 billion in 2022 and is expected to reach USD 11.6 billion in 2023.
b. The global bioinformatics market is expected to grow at a compound annual growth rate of 13.7% from 2023 to 2030 to reach USD 28.5 billion by 2030.
b. North America dominated the bioinformatics market with a share of 43.56% in 2022. This is attributable to the rising healthcare awareness and increasing research and development activities in the region.
b. Some key players operating in the bioinformatics market include BIOVIA, IBM Life Sciences, Life Technologies Corporation, Illumina Inc., 3rd Millennium Inc., Agilent Technologies, Affymetrix, Celera Corporation, Rosetta Biosoftware, and BioWisdom Ltd.
b. Key factors that are driving the market growth include rise in demand of time & cost-effective tools and techniques for drug discovery, increased adoption of bioinformatics in clinical diagnostics & personalized medicine, rapid development in computing & integrated web services, rise in the number of collaborations among bioinformatics companies, research institutes, and healthcare providers, presence of favorable government initiatives & external funding for R&D exercises.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
"The quality of research they have done for us has been excellent."